-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $47

Benzinga·12/18/2025 15:50:43
Listen to the news
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $50 to $47.